Marksans Pharma Limited to report Q2 FY27 results November 4

Marksans Pharma Limited is scheduled to consider and approve its unaudited standalone and consolidated Q2 FY27 results on November 4, 2026, following Q1 revenue reported as 840 and year-on-year growth of 35.62%. The board meeting will also cover half-year results for the period ended September 30, 2026.

When will Marksans Pharma announce Q2 FY27 results?

Marksans Pharma is scheduled to announce its Q2 FY27 financial results on November 4, 2026. The company informed the BSE that its board meeting will consider and approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.

The date is significant because it is the next formal update on operating performance after the June-quarter results released on August 12, 2026. A separate listing describes the Q2 FY27 results as expected on November 4 and states that the company planned to report at 12:08 PM Indian Standard Time. The board-meeting intimation remains the key regulatory disclosure on the results process.

What has Marksans Pharma disclosed before the results date?

Marksans Pharma has issued several filings connected with the September-quarter reporting cycle. On September 7, 2026, it announced the closure of its trading window for the quarter and half year ended September 30. Such closures restrict trading by designated persons while unpublished price-sensitive information is being prepared and reviewed.

On October 26, the company filed an intimation under Regulation 30 of the Listing Obligations and Disclosure Requirements Regulations regarding the schedule for its Q2 FY27 earnings conference call. The disclosed material confirms that an analyst and investor interaction is planned, although the supplied information does not provide the call's date, time, or access details.

The company had earlier released its Q1 FY27 investor presentation on August 12. Its board approved unaudited consolidated and standalone financial results for the quarter ended June 30 on the same date. Investors will be able to compare the September-quarter disclosures with these Q1 materials once the updated results and presentation are filed.

What do the available Q1 FY27 figures show?

The available Q1 FY27 data shows revenue of 840, down 1.79% quarter on quarter but up 35.62% from a year earlier. Gross profit was reported at 188, with quarter-on-quarter growth of 9.96%. The supplied data does not state the monetary unit for these figures, so they are presented as disclosed rather than converted into a presumed unit.

The difference between revenue movement and gross-profit movement is relevant for investors reviewing the next result. Revenue declined sequentially in the supplied comparison, while gross profit increased sequentially. However, the source does not provide gross-margin percentages, expenses, profit after tax, debt, cash flow, or segment-level results. Those details should therefore not be inferred ahead of the filing.

Why does the September-quarter update matter for investors?

Marksans Pharma's Q2 FY27 filing will provide the first official financial view of the business for the quarter ended September 30. It will also include half-year numbers, allowing investors to assess the June and September quarters together rather than relying only on a single quarter's growth rates.

The supplied Q1 data establishes a high year-on-year revenue comparison of 35.62%, while also showing a 1.79% sequential revenue decline. The Q2 outcome will show whether the prior year's growth rate, the quarter-on-quarter revenue movement, and the reported gross-profit trend changed during the September quarter. These are factual comparison points, not forecasts of the upcoming result.

The results are also relevant because the company operates in the generics and consumer-health category on the National Stock Exchange of India under the ticker MARKSANS. Financial disclosures, the investor presentation, and the scheduled conference call can help shareholders evaluate management's reported performance using primary company information.

What corporate actions accompany the Q2 FY27 reporting cycle?

Marksans Pharma declared a dividend of Rs 0.90 per share on August 20, 2026. The declaration followed the Q1 results period, but the supplied information does not specify the record date, payment date, or total dividend outgo. Investors should refer to the relevant corporate-action filing for those details.

The company also held its 34th Annual General Meeting on August 27, 2026, according to the available event information. Together with the Q1 investor presentation and the forthcoming Q2 call, these disclosures provide a documented sequence of investor communication during FY27. The November 4 filing will be the next material results-related update in that sequence.

Conclusion

Marksans Pharma's November 4 board meeting is the confirmed date for consideration of Q2 FY27 and first-half unaudited standalone and consolidated results. The available Q1 figures show reported revenue of 840, 35.62% year-on-year growth, and reported gross profit of 188, but the monetary unit and several profitability metrics were not supplied.

Investors should watch for the official results filing, the accompanying investor presentation, and details from the announced Q2 FY27 earnings conference call. Particular attention will be on the company’s disclosed revenue, profitability, cash flow, and management commentary for the quarter and half year ended September 30, 2026.